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Soluble biomarkers in OA: can
they be used as indicator of HA
re-injection?
Osteoarthritis: A global disease
affecting all joint tissues
…to identify metabolic






















To decrease « degradative peptides » release is a therapeutic target
« Metabolic responders »














These signs and symptoms occur in the late stage of the 
disease
Radiographic and clinical signs are 
preceeded by a silent molecular phase






































…To diagnose the disease at the silent molecular phase
Drug discovery is protracted, risky and 
costly
Nothing new to offer at the 
patients and the OA research 
community
Clinical trials end-point




 Structure modification (1 to 3 years)
Imaging outcomes
Joint Space Narrowing
The main limitations of JSN 
 Indirect measure of the alteration in 
articular cartilage.
 Fails to measure a dynamic process
 Confounded by the presence of 
meniscal lesions and extrusion.
 Changes overtime are small, and occur 
in only a subset (progressors) of patients.
 Poorly reproducible (full extension).
 Poorly correlated with joint function and 
pain. 
Why do we need biological markers in treatment
developement?
 To predict who will respond to a 
treatment
 To surrogate clinical end-point 
 To monitor the effect on tissue 
metabolism
FDA and EMA 
recommendations
 “a higher level of integration of biomarkers 
in the development and testing of new 
drugs to advance decision-making on 
dosing, time and treatment effect, trial 
design, and risk/benefit analysis . Biomarkers 
can be used not only in the process of drug 
development, but also in assessment of 
individual patient’s response to treatment.”















Soluble or « wet » biomarkers « Dry » biomarkers
A biomarker is a characteristic that is objectively measured
and evaluated as an indicator of normal biologic processes, 
pathogenic processes, or pharmacologic responses to a 
therapeutic intervention. » 
Biomarkers Definitions Working Group I. Biomarkers and surrogate endpoints: preferred definitions















































































Bauer et al. Osteoarthritis Cart 2006
• Biomarker associated with extent of severity of OABurden of disease
• Biomarker not yet meeting criteria for another
categoryInvestigative
• Predicts incidence of progression of disease or 
likelihood of response to a treatmentPrognostic
• Indicative of treatment efficacy and for which the 
magnitude of the change is considered pertinent to 
the response. 
Efficacy of treatment
• Dissociate diseased from non-diseased.Diagnostic
• Identify adverse effects and provide means of 
safety.oneSafety
Efficacy of intervention
« Indicative or predictive of 
treatment efficacy and for 
which the magnitude of the 
change is considered
pertinent to the response. »
Biomarkers of efficacy of treatment (BIPEDS)
Updated Van Spil et al.2010
BIPEDS Biomarkers
Efficacy of intervention uCTX-II, sColl2-1,sCOll2-1NO2, sC2C, 
sCOMP, sKS, sYLK40, sPIIANP, uNTX-
I, sOC,  sHA, sMMP-3, sCRP
« Biochemical marker concentration 
differed statistically significantly
between patient populations  with or 
without treatment, or before and 
after treatment within patient »















Richette, Roux Osteoporosis Int 2012
u CTX-II reflects
bone rather than cartilage
metabolism
van Spil W E et al. Ann Rheum Dis 2013
BIOVISCO study: Study design






1NO2, s C2C, sCOMP, 
sCS-846, sCPII,CTX-II
Henrotin Y et al. Journal of Orthopaedic Research
19 FEB 2013
BIOVISCO study
An open label observational prospective study
Conrozier et al, J Orthp Res, 2012; Henrotin et al, J Orthp Res,2013.
D1 
(after the last injection)
90 days
(after the last injection)
p-Value
D1 vs D90
sColl2-1 (nM) 140.34(882.44-285.32) 128.41 (85.6-241.34) 0.05*
sColl2-1NO2 (nM) 0.400 (0.050-1.010) 0.370 (0.14-0.870) 0.025*
uCTX-II (ng/nmolcreat) 392.7 (90.0-816.4) 306.0 (90-1123.9) 0.02*
sPIICP (ng/ml) 817.9 (131.4-1848.6) 874.8.3 (326.4-1435.0) 0.41
sC2C (ng/ml) 223.6 (99.4-329) 209.5 (135.9-291.7) 0.11
sCOMP (U/L) 10.9 (6.0-20.2) 10.5 (6.0-20.0) 0.82
sCS846 (ng/ml) 99.8 (45.9-172.3) 102.2 (53.0-190) 0.38
sHA (ng/ml) 34.1 (15.4-211) 33.3 (9.5-230.1) 0.38
 45 patients with unilateral symptomatic tibiofemoral and/or patellofemoral OA
 3-weekly intraarticular injection of hyalan G20 (Synvisc®)
 Follow-up D1, D30 and D90 after the last injection
20
Coll2-1 and Coll2-1NO2: 










 Specific of degradated cartilage






Only sColl2-1 was significantly decreased 30 days after final injection
Only uCTX-II variation correlated with clinical response (walking pain decrease)
uCTX, sColl2-1 and sHA were independently predictive of clinical response











Day 30 Day 0
The concept of 
« metabolic » responders
 ACCORDING TO CLINICAL TRIAL RESULTS, SOME PATIENTS DID
RESPOND TO THE TREATMENT IN TERM OF CATABOLISM
REDUCTION BUT OTHERS DID NOT.
The EPIKART study
ARD 2016, under submission
The EPIKART study
 A 6-month prospective, randomized, 
double blind, controlled study
 A single injection of KARTILAGE® Cross 
or  saline solution
 Primary outcome
the variation of Coll2-1 in serum between 
inclusion visit (D-10) and D90 (3 months after 
injection)
Inclusion criteria
 Men or women aged between 45 and 
80 years old
 With symptomatic femoro-tibial OA
 VAS > 40 mm
















BMI (kg/m2) 29.0 ± 7.4 30.8 ± 7.2 0.2465
Demographic data of the FAS population (N=81)









Serum Coll2-1 at D-10 





Serum Coll2-1 at D90
745.4 ± 343.5 
(N=37)
782.3 ± 233.7 
(N=35)
0.5975 
Adjustment on basal value -80.2 ± 44.1 -14.6 ± 45.3 0.0030 
Reduction of at least 10 
nmol/l
56.8 % 28.6 % 0.0158 
Conclusions
 A single injection of KARTILAGE®Cross
induced a reduction of Coll2-1 30 days
after treatment
→sensibility of the biomarker to a 
single joint metabolic change
→IAHA modulate cartilage 
catabolism « chondromodulator »
→Confirmatory study
Conclusions
 No clinical effect
Concept of « metabolic
responders » ≠ « symptomatic
responders »








To use a specific biomarker of cartilage 




 Notion of « metabolic responders »
 Therapeutic algorithm to identify the 
IAHA responders
 Coll2-1 alone or in « aggregate score » 
as indicator of reinjection
 Personalized approach of the 
viscosupplementation
Statements
 The effect of viscosupplementation on cartilage 
metabolism is a valuable outcome in the follow-up 
of OA patients.
 Soluble biomarkers are good tools/useful for 
monitoring the effects of viscosupplementation on 
cartilage metabolism.
 Soluble biomarkers are predictive of the response to 
viscosupplementation.
 Soluble biomarkers variation can be used as 
indicator of HA re-injection
Thank you for your attention !
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